Hervé Dombret

Learn More
PURPOSE In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk(More)
Patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL) have a rapid disease course and a poor prognosis. Dasatinib, a novel, oral, multitargeted kinase inhibitor of(More)
By Pierre Fenaux, Claude Chastang,† Sylvie Chevret, Miguel Sanz, Hervé Dombret, Eric Archimbaud,† Martin Fey, Consuelo Rayon, Françoise Huguet, Jean-Jacques Sotto, Claude Gardin, Pascale Cony(More)